The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.

Bladder cancer (BCa) shows its potential immunogenity in current immune-checkpoint inhibitor related immunotherapies. However, its therapeutic effects are improvable and could be affected by tumor immune microenvironment. Hence it is interesting to find some more prognostic indicators for BCa patients concerning immunotherapies.

In the present study, we retrospect 129 muscle-invasive BCa (MIBC) patients with radical cystectomy in Shanghai General Hospital during 2007 to 2018. Based on the results of proteomics sequencing from 9 pairs of MIBC tissue from Shanghai General Hospital, we focused on 13 immune-related differential expression proteins and their related genes. An immune-related prognostic signature (IRPS) was constructed according to Cancer Genome Atlas (TCGA) dataset. The IRPS was verified in ArrayExpress (E-MTAB-4321) cohort and Shanghai General Hospital (General) cohort, separately. A total of 1010 BCa patients were involved in the study, including 405 BCa patients in TCGA cohort, 476 BCa patients in E-MTAB-4321 cohort and 129 MIBC patients in General cohort.

It can be indicated that high IRPS score was related to poor 5-year overall survival and disease-free survival. The IRPS score was also evaluated its immune infiltration. We found that the IRPS score was adversely associated with GZMB, IFN-γ, PD-1, PD-L1. Additionally, higher IRPS score was significantly associated with more M2 macrophage and resting mast cell infiltration.

The study revealed a novel BCa prognostic signature based on IRPS score, which may be useful for BCa immunotherapies.

BMC cancer. 2022 Jun 20*** epublish ***

Liren Jiang, Siteng Chen, Qi Pan, Jun Zheng, Jin He, Juanjuan Sun, Yaqin Han, Jiji Yang, Ning Zhang, Guohui Fu, Feng Gao

Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Hai Ning Road, Shanghai, 200080, China., Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin 2nd Road, Shanghai, 200020, China. ., Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Institutes of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ., Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Hai Ning Road, Shanghai, 200080, China. .